Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY announces Pelareorep ≥50% ORR & mPFS Improvements

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 26, 2023 12:30pm

123 Views

Post# 35465955

RE:RE:RE:RE:RE:ONCY announces Pelareorep ≥50% ORR & mPFS Improvements

ONCY's Bracelet-1 Phase 2 trial had enrolled heavily pre-treated who had failed earlier therapy including CDK 4/6 inhibitors that Pfizer, Novartis and Eli Lilliy currently have on the market.

https://www.globenewswire.com/en/news-release/2022/01/27/2374587/0/en/Global-CDK-4-6-Inhibitor-Drugs-Market-to-Witness-Remarkable-Growth-Backed-by-Growing-Incidences-of-Breast-Cancer-Worldwide-Market-to-Generate-a-Soaring-Revenue-of-USD-42511-38-Mill.html

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?